Cholesterol drug market heating up with new entrant

07/19/2004 | Financial Times (free content)

If the FDA gives its approval this week, a new competitor will enter the $25 billion to $35 billion market for lowering cholesterol. With that approval, Vytorin, from Schering-Plough and Merck, would be joining Crestor, from AstraZeneca, in trying to take market share away from Pfizer's Lipitor. Vytorin is a combination of Zocor and Zetia and is seen as the strongest Lipitor competitor, with a study this year showing it reduced cholesterol more effectively than Lipitor.

View Full Article in:

Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC